GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Notes Receivable

Tryptamine Therapeutics (ASX:TYP) Notes Receivable : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Notes Receivable?

Tryptamine Therapeutics's Notes Receivable for the quarter that ended in Dec. 2024 was A$0.00 Mil.


Tryptamine Therapeutics Notes Receivable Historical Data

The historical data trend for Tryptamine Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Notes Receivable Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Notes Receivable
Get a 7-Day Free Trial - - - - -

Tryptamine Therapeutics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tryptamine Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Tryptamine Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Tryptamine Therapeutics Business Description

Traded in Other Exchanges
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

No Headlines